Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Pulmatrix Inc PULM

Healthcare
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PULM)

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

PR Newswire March 28, 2024

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

PR Newswire January 8, 2024

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire November 9, 2023

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

PR Newswire September 19, 2023

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

PR Newswire August 23, 2023

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire August 10, 2023

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

PR Newswire July 11, 2023

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

PR Newswire June 15, 2023

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

PR Newswire May 24, 2023
View More News ››

Opinion & Analysis (NDAQ:PULM)

Pulmatrix's Licensing Deal with the JNJ Lung Cancer Initiative Sends Shares Up 100%

Streetwise Reports January 3, 2020
View More Opinion ››

Bullboard Posts (NDAQ:PULM)

it's a buy today for me

it looks like its time has come to perform,off my watchlist,so glta shareholders.
coolfooldumbguy - January 2, 2020

watching this one for

an entry point,but not yet,so glta.
coolfooldumbguy - April 4, 2019

RE:RE:Wainwright Report $5 Target

However the incompetent finance team issues yet another awful financing. Only an idiot would issue more warrants st this stage. Total...
dmacd - April 4, 2019

RE:Wainwright Report $5 Target

A nice day for sure and validates what a few of us have known for some time now that the company was ridiculously undervalued. The deal...
dmacd - April 1, 2019

Wainwright Report $5 Target

Discounted success by 10 factor so max upside is $50/sh based on assumptions. Indicates $15M/a spend till 2023 but didn't factor in...
dmacd - March 12, 2019

Interesting Run

Nice run on no news. Good volume. Hmmmm.
dmacd - March 8, 2019
View more Bullboard ››

New Pacific Metals Corp.

New Pacific Metals Corp.

New Pacific Metals Corp. is a Canada-based exploration and development company, which is focused on three precious metal ...
View More »